Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
(NASDAQ:ALNY) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA Phase II program, including KARDIA-1, KARDIA-2 and
Related Questions
How will the initiation of a Phase III CVOT for Zilebesiran affect Alnylam's revenue forecasts and valuation multiples?
What are the potential competitive risks from other RNAi or hypertension therapies in development, and how might they influence market share?
What timelines and milestones (e.g., trial enrollment, data readout) should traders monitor for price volatility and catalyst events?